Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.
Press releases published on May 27, 2025
Junshi Biosciences Announces Ongericimab’s sNDA Approval in China
GlobeNewswire
·
May 27, 2025
SHANGHAI, May 27, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel …
MIMEDX to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 27, 2025
MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 22nd Annual …
Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease
GlobeNewswire
·
May 27, 2025
LONDON, May 27, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced the publication of preclinical proof-of-concept data for FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease in Molecular Therapy, the flagship …
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
GlobeNewswire
·
May 27, 2025
- Study will assess relative efficacy, safety, and immunogenicity of Vaxart’s oral pill COVID-19 vaccine candidate against an approved mRNA comparator at 12 months - SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) …
DeepView® System Achieves 95.3% Accuracy Evaluation as Published in Burns Journal
GlobeNewswire
·
May 27, 2025
DALLAS, May 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) (“Spectral AI” or the “Company”), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today …
NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
GlobeNewswire
·
May 27, 2025
-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary safety endpoint, …
ORYZON to Provide Corporate Progress Updates at Several Events in May-June
GlobeNewswire
·
May 27, 2025
Foro MedCap 2025 BIO International Convention 2025 Discovery and Development Europe 2025 MADRID and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a …
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
GlobeNewswire
·
May 27, 2025
NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory …
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
GlobeNewswire
·
May 27, 2025
Ms. Kline to lead Palvella’s commercial buildout for planned standalone U.S. launch of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estimated …
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025
GlobeNewswire
·
May 27, 2025
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it will present data at the 62nd European …
SciSparc Announces Publication of Japanese Patent Application
GlobeNewswire
·
May 27, 2025
TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central …
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
GlobeNewswire
·
May 27, 2025
Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and …
Evaxion announces business update and first quarter 2025 financial results
GlobeNewswire
·
May 27, 2025
COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2025 financial results. Business …
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor
GlobeNewswire
·
May 27, 2025
Bria-OTS has cleared its safety evaluation in the Phase 1/2 study monotherapy dosage setting Phase 1/2 study has now transitioned to dosing patients in combination with checkpoint inhibitor in metastatic breast cancer First Bria-OTS monotherapy patient …
Adagene to Present at Jefferies Global Healthcare Conference 2025
GlobeNewswire
·
May 27, 2025
SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy Officer, Mickael …
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
GlobeNewswire
·
May 27, 2025
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 …
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
GlobeNewswire
·
May 27, 2025
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced a strategic collaboration to …
Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report
GlobeNewswire
·
May 27, 2025
WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related …
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
GlobeNewswire
·
May 27, 2025
MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United States Food and Drug Administration (U.S. FDA) …
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2…
GlobeNewswire
·
May 27, 2025
CANOPY assessed pemivibart safety and tolerability, antiviral immunobridging, and exploratory efficacy against COVID-19, and is the only clinical trial of an authorized or approved COVID-19 monoclonal antibody or vaccine with placebo-controlled clinical …